信達生物(01801.HK)5,000萬美元入股亞盛醫藥(06855.HK) 開展戰略合作
信達生物(01801.HK)公佈,與亞盛醫藥-B(06855.HK)開展多層面戰略合作,以聯合商業化HQP1351,並對CD20抗體達伯華(利妥昔單抗注射液)及CD47抗體IB188(letaplimab)和Bcl-2抑制劑APG-2575合作臨牀開發。
此外,公司將認購亞盛醫藥合共882.38萬股新股,佔其股本3.48%,每股作價44元,較上交易日(14日)收報折讓16.90%,總值即約5,000萬美元。同時,獲授予涉及合共678.75萬股認股權證股份,佔其股本2.67%,每股認購價57.2元。
根據HQP1351合作及授權協議,雙方體將共同負責HQP1351往後在內地、香港、澳門及臺灣內的研發工作,新藥上市申請獲批後,將共同商業化推廣,並按照50%:50%對來自共同推廣部分的利潤進行分成。
信達蘇州將向亞盛實體支付3,000萬美元的首付款。取決於HQP1351達到若幹開發註冊裏程碑及獲批在有關地區內銷售時達到若幹年度銷售表現裏程碑,亞盛醫藥將有資格獲得累計不超過1.15億美元的裏程碑付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.